Inflammation as a key driver of cardiovascular disease
In a landmark 2025 Scientific Statement from the American College of Cardiology, published in the Journal of the American College of Cardiology (JACC), a panel of experts presents a comprehensive update on the role of inflammation in cardiovascular disease (CVD). The statement argues decisively that the link between chronic, low-grade inflammation and atherosclerotic cardiovascular disease (ASCVD) has moved beyond the exploratory phase and is now a compelling, clinically actionable reality. The authors call for a paradigm shift in clinical practice, advocating for near-universal screening for inflammation and the adoption of targeted anti-inflammatory therapies as a standard component of cardiovascular risk reduction.
The Evolution of Understanding: From Hypothesis to Actionable Science
The statement begins by contextualizing the current moment, contrasting it with a more cautious 2002 workshop by the CDC and American Heart Association. While that earlier meeting identified high-sensitivity C-reactive protein (hsCRP) as a promising biomarker, it stopped short of recommending widespread screening due to insufficient evidence. Over the subsequent two decades, a wealth of basic, clinical, and population science research has solidified the understanding that chronic, silent inflammation is a pivotal driver of atherosclerotic plaque formation, progression, rupture, and subsequent thrombotic events. This new body of evidence, anchored by several large-scale, randomized clinical trials, forms the basis for the statement's assertive "call to action."
The central thesis is that clinicians "will not treat what they do not measure." Therefore, the time has come to integrate the assessment and management of inflammatory risk into routine cardiovascular care alongside traditional risk factors like cholesterol and blood pressure.
Biomarkers and Risk Assessment: The Centrality of hsCRP
The document firmly establishes hsCRP as the primary, standardized, and most clinically useful biomarker for assessing silent vascular inflammation.
- Risk Stratification: The statement reiterates the established clinical thresholds for hsCRP:
- <1 mg/L: Lower relative risk
- 1 to 3 mg/L: Average relative risk
- >3 mg/L: Higher relative risk
- Predictive Power: The authors present powerful evidence demonstrating that hsCRP's prognostic value is comparable, and in some cases superior, to that of LDL cholesterol. A prospective study of nearly 28,000 women followed for 30 years found that a single baseline hsCRP measurement provided a greater spread of risk for future cardiovascular events than either LDL cholesterol or lipoprotein(a). This underscores that inflammation is not merely a bystander but a potent, independent contributor to cardiovascular risk.
- Clinical Recommendation: Based on this evidence, the committee makes a major consensus recommendation for the universal screening of hsCRP in both primary and secondary prevention patients, in conjunction with cholesterol assessment. While other biomarkers like interleukin-6 (IL-6) and fibrinogen also predict risk, hsCRP remains the most practical and well-validated tool for clinical use.
Imaging biomarkers, such as the perivascular fat attenuation index derived from CT scans, are noted as promising research tools for identifying localized vascular inflammation but are not yet recommended for routine clinical settings.
Inflammation in Primary Prevention
In individuals without known CVD, elevated hsCRP is an unequivocal predictor of future events. A meta-analysis encompassing over 160,000 individuals showed that a one-standard-deviation increase in hsCRP was associated with a 37% increased risk of coronary heart disease and a 55% increased risk of cardiovascular death. The prevalence of this risk is substantial, affecting up to 50% of adults in the United States who have an hsCRP level of 2 mg/L or higher.
The cornerstone of therapeutic evidence in this setting is the JUPITER trial. This study enrolled individuals with normal LDL cholesterol (<130 mg/dL) but elevated hsCRP (≥2 mg/L). Treatment with rosuvastatin resulted in a remarkable 47% reduction in the primary endpoint of major cardiovascular events. This trial definitively proved that a therapy with anti-inflammatory effects provides significant benefit in a population selected for inflammatory risk, even when cholesterol levels are not elevated.
- Consensus Recommendation: For primary prevention, a persistently elevated hsCRP level should prompt consideration of initiating or intensifying statin therapy, irrespective of the patient's LDL cholesterol level. Early lifestyle interventions are also strongly recommended.
Secondary Prevention and Residual Inflammatory Risk
For patients with established CVD, the concept of "residual inflammatory risk" is critical. This refers to the persistent high risk of recurrent events in individuals who have elevated hsCRP despite being on statin therapy and having well-controlled LDL cholesterol.
- Predictive Power in Statin Users: An analysis of over 31,000 statin-treated patients from the PROMINENT, REDUCE-IT, and STRENGTH trials found that hsCRP was a stronger predictor of recurrent cardiovascular events and death than LDL cholesterol. Patients with hsCRP >2 mg/L remained at high risk even if their LDL was below 70 mg/dL, highlighting a significant unmet clinical need.
The statement highlights two seminal trials that have validated direct anti-inflammatory therapy:
- CANTOS Trial: This trial provided the definitive proof-of-principle for the inflammation hypothesis of atherothrombosis. Patients with a prior myocardial infarction and hsCRP ≥2 mg/L were treated with canakinumab, an antibody that inhibits the IL-1β to IL-6 inflammatory pathway. The treatment resulted in a 15% to 17% reduction in recurrent vascular events without any change in LDL cholesterol levels.
- COLCOT and LoDoCo2 Trials: These trials demonstrated that low-dose colchicine (0.5 mg daily), an inexpensive and widely available anti-inflammatory agent, reduced recurrent cardiovascular events by approximately 25% in patients with chronic stable atherosclerosis. This led to colchicine becoming the first FDA-approved anti-inflammatory agent specifically for reducing cardiovascular risk in this population. The statement notes that while one trial (CLEAR-SYNERGY) showed no benefit when initiated in the acute post-MI setting, updated meta-analyses that include these data still confirm an overall 25% relative risk reduction for major adverse cardiovascular events.
- Consensus Recommendation: For secondary prevention, hsCRP is a powerful predictor of recurrent events. If hsCRP remains >2 mg/L in a statin-treated patient, intensification of the statin dose should be considered. Furthermore, low-dose colchicine is recommended as an adjunct to lipid-lowering therapy for patients with chronic stable atherosclerosis.
Broader Implications: Lifestyle, Heart Failure, and Pericarditis
The statement extends the role of inflammation beyond atherosclerosis:
- Behavioral and Lifestyle Risks: Proinflammatory dietary patterns are linked to higher CVD risk, whereas anti-inflammatory diets like the Mediterranean diet (as shown in the PREDIMED trial) reduce major cardiovascular events. The committee recommends at least 150 minutes per week of moderate exercise, smoking cessation, and maintaining a healthy weight as powerful anti-inflammatory strategies.
- Heart Failure (HF): HF is characterized by a chronic, low-grade inflammatory state. While many anti-inflammatory trials in HF have failed, some important positive signals have emerged. The GISSI-HF trial showed that 1g daily of omega-3 fatty acids (EPA+DHA) modestly reduced mortality. A sub-analysis of the CANTOS trial also revealed that canakinumab produced a dose-dependent reduction in hospitalizations for HF.
- Recurrent Pericarditis: This is an area where anti-inflammatory therapy is already the standard of care. The ICAP trial showed that colchicine reduced recurrences by 50%. For patients with severe, resistant pericarditis (hsCRP >10 mg/L), targeted IL-1 blockade has proven highly effective, reducing recurrence rates from as high as 90% to below 20%.
Call to Action: A New Era in Cardiovascular Prevention
The statement concludes with an emphatic call to action. The evidence linking inflammation to ASCVD is now robust enough to demand changes in clinical practice. The writing committee urges that clinical practice guidelines be updated to:
- Implement broad screening for hsCRP in both primary and secondary prevention patients.
- Embrace anti-inflammatory interventions, such as colchicine, for patients with established ASCVD and residual inflammatory risk, regardless of their LDL cholesterol level.
- Promote physician awareness and accelerate the adoption of guideline-directed anti-inflammatory therapy.
By endorsing inflammation biology, clinicians can also reinforce the importance of lifestyle interventions like diet, exercise, and weight control, all of which lower hsCRP. The era of treating inflammation as a key target in cardiovascular medicine has, according to this statement, officially arrived.



